Novozymes A/S (NVZMY)
Novozymes A/S (NVZMY) Stock Price, Analysis & Data
No data available
| Bid | 65.54 |
| Market Cap | 30.6B |
| Revenue (ttm) | 4.2B |
| Net Income (ttm) | 596.7M |
| Beta | 0.62 |
| EPS (ttm) | 1.48 |
| PE Ratio (ttm) | 44.35 |
| Forward PE | 24.7 |
| P/B (ttm) | 2.41 |
| P/S (ttm) | 7.29 |
| Earnings Date | Aug 20, 2026 |
| Ask | 65.63 |
| Volume | 4,091 |
| Avg. Volume (20D) | 37,911 |
| Open | 65.68 |
| Previous Close | 64.19 |
| Day's Range | 65.28 - 65.77 |
| 52-Week Range | 49.90 - 66.66 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $1 (1.53%) |
| Ex-Dividend Date | Mar 25, 2026 |
About NVZMY
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including bi...
Financial Performance
In 2025, Novozymes A/S's revenue was 4.16B, an increase of 8.45% compared to the previous year's 3.83B. Earnings were 583.6M, an increase of 90.84%.
Financial StatementsEarnings Surprise
Analysts project revenue of ... Upgrade
4 months ago · Simply Wall St.
Novozymes Dividend Increase And Valuation Discount Catch Investor AttentionNovozymes (CPSE:NSIS B) has approved a higher ordinary dividend at its recent Annual General Meeting. The new dividend level was formally adopted by shareholders as part of the AGM resolutions. The de...